Ibtrozi™ (taletrectinib) – New orphan drug approval
June 11, 2025 - The FDA announced the approval of Nuvation Bio’s Ibtrozi (taletrectinib), for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Download PDF